NASDAQ: CNSPCns Pharmaceuticals Inc Stock
$2.07-0.03 (-1.43%)
Updated Dec 8, 2023
CNSP Price
$2.07
Fair Value Price
$4.75
Market Cap
$10.86M
52 Week Low
$0.61
52 Week High
$4.40
P/E
-0.25x
P/B
-6.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.34
Operating Cash Flow
-$14M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNSP Overview
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CNSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNSP ($2.07) is undervalued by 56.43% relative to our estimate of its Fair Value price of $4.75 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CNSP ($2.07) is significantly undervalued by 56.43% relative to our estimate of its Fair Value price of $4.75 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNSP due diligence checks available for Premium users.
Be the first to know about important CNSP news, forecast changes, insider trades & much more!
CNSP News
Valuation
CNSP fair value
Fair Value of CNSP stock based on Discounted Cash Flow (DCF)
Price
$2.07
Fair Value
$4.75
Undervalued by
56.43%
CNSP ($2.07) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNSP ($2.07) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
11.7x
Market
31.32x
CNSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.24x
Industry
5.42x
CNSP's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.5M
Profit Margin
0%
CNSP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.3M
Liabilities
$4.1M
Debt to equity
-2.34
CNSP's short-term liabilities ($4.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNSP's short-term assets ($2.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNSP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CNSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$1.7k
Financing
$8.4k
CNSP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNSP vs Biotech Stocks
Cns Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.